RESprotect is a Dresden-based biotech company that specializes in the development of drugs for the prevention and treatment of chemotherapeutic drug resistance and radiation therapy resistance. As a privately held company, RESprotect is dedicated to finding innovative solutions to combat these challenges. Their first product candidate, RP101, is a small molecule drug administered orally to cancer patients in combination with standard chemotherapy.

Clinical studies have shown that patients with advanced pancreatic cancer who received RP101 achieved significantly improved survival compared to those receiving standard chemotherapy alone. RESprotect's commitment to cutting-edge research and development sets them apart in the industry. With a focus on preventing chemoresistance, they strive to provide effective solutions for patients facing drug resistance during cancer treatment.

Visit their website to learn more about their product portfolio and ongoing clinical trials